Sign in
Taking people in FranceNo phase

Studying good cholesterol function in type 1 diabetes with kidney disease

Compares blood and urine samples in adults with type 1 diabetes and kidney disease.

Key facts

Who runs it
Centre Hospitalier Universitaire Dijon
Where
Dijon, FranceSee the site
Trial code
Registry title
Study of High Density Lipoprotein Function in Type 1 Diabetic Patients With Nephropathy
Status
Recruiting
People taking part
200 people, planned
Started
24 Apr 2018
Expected to end
Oct 2027
Type of study
Observational, 5 groups
Treatments tested
  • Blood samples
  • Urine sample
Record updated
30 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 1 diabetes, with or without kidney damage (protein in the urine), and adults without diabetes as a comparison group. Blood and urine samples are taken.

Age
Over 18 years
Sex
Men and women
Disease stage
Type 1 diabetes with normal albumin in the urine, with microalbuminuria, or with macroalbuminuria. Kidney filtration rate over 90 mL/min/1.73m2 (over 45 for macroalbuminuria). A comparison group has no diabetes.
Earlier treatment
Cannot take drugs that affect fats in the blood, other than insulin for type 1 diabetes.
Biomarker or test result
Type 1 diabetes patients: HbA1c between 6 and 9% (42–75 mmol/mol). Albumin in the urine as described for each group. Comparison group: fasting blood glucose under 6.10 mmol/L (110 mg/dL), triglycerides under 1.7 mmol/L (151 mg/dL), HDL cholesterol over 1.30 mmol/L (50 mg/dL) for women and 1.03 mmol/L (40 mg/dL) for men.

Main reasons for not taking part

  • Protected adult
  • Not covered by a social security scheme
  • Pregnant or breastfeeding woman
  • Taking drugs that interfere with fat metabolism, such as corticosteroids, estroprogestogens, retinoic acid or antiproteases
  • BMI over 30 kg/m2

The registry criteria, word for word

Show all 30 criteriaShow less

Who can take part

  • age > 18 years
  • a person who has given oral consent
  • Non-diabetics
  • Fasting plasma glucose < 6.10 mmol/L (1.1 g/L)
  • Triglyceridemia < 1.7 mmol/L (1.5 g/l)
  • HDL-C concentration > 1.30 mmol/L (for women and 1.03 mmol/L for men)
  • Glomerular filtration flow rate > 90 mL/min/1.73m2 (These thresholds correspond to the standard thresholds for these parameters)
  • age > 18 years
  • a person who has given oral consent
  • Diabetic type 1 (based on the patient's clinical history and/or the presence of anti-glutamate decarboxylase autoantibodies and/or plasma C-peptide less than 0.5 ng/l)
  • HbA1c between 6 and 9%
  • normal albuminuria (albumin/creatinine ratio < 2.5 mg/mmol in men and < 3.5 in women)
  • glomerular filtration rate > 90 mL/min/1.73m2
  • age > 18 years
  • a person who has given oral consent
  • Diabetic type 1 (based on the patient's clinical history and/or the presence of anti-glutamate decarboxylase autoantibodies and/or plasma C-peptide less than 0.5 ng/l)
  • HbA1c between 6 and 9%
  • Microalbuminuria (albumin/creatinine ratio > 2.5 mg/mmol in men and > 3.5 in women, and < 30 mg/mmol)
  • glomerular filtration rate > 90 mL/min/1.73m2
  • age > 18 years
  • a person who has given oral consent
  • Diabetic type 1 (based on the patient's clinical history and/or the presence of anti-glutamate decarboxylase autoantibodies and/or plasma C-peptide less than 0.5 ng/l)
  • HbA1c between 6 and 9%
  • Macroalbuminuria (albumin/creatinine ratio > 30 mg/mmol)
  • glomerular filtration rate > 45 mL/min/1.73m2

Who cannot take part

  • Drugs interfering with lipid metabolism outside insulin for DT1 : hypolipidemic (only for patients included in the DT1-micro group), corticosteroid, estroprogestogens, retinoic acid, antiproteases
  • Protected adult
  • Patient not affiliated to a social security scheme
  • Pregnant or breastfeeding woman
  • BMI > 30 kg/m2

Where in France

  • Chu Dijon BourogneDijon, FranceContact: Laurence DUVILLARDTaking people

About the trial

What the trial wants to find out

A number of arguments suggest that the deterioration in high density lipoproteins (HDL) functioning may worsen with the development of nephropathy during type 1 diabetes (T1D).

Read full original descriptionShow less

The objective of this study will be to investigate to what extent nephropathy in T1D patients in the microalbuminuria and macroalbuminuria stages, compared to T1D patients without nephropathy, is associated with an alteration in HDL functionality and changes in HDL size and composition (lipids with detailed study of phosphates and sphingolipids, main lipoproteins, inflammatory markers).

The 5 groups in the trial

  • control

    Treatment: Blood samples and Urine sample

  • T1D with normal albumin levels

    Treatment: Blood samples and Urine sample

  • T1D with macroalbuminuria

    Treatment: Blood samples and Urine sample

  • T1D with microalbuminuria

    Treatment: Blood samples and Urine sample

  • T1D with microalbuminuria and statins

    Treatment: Blood samples and Urine sample

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Study of High Density Lipoprotein Function in Type 1 Diabetic Patients With Nephropathy
Plain-language title
Studying good cholesterol function in type 1 diabetes with kidney diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
30 October 2026